provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
Pluvicto Coupon - Pluvicto 30ml of 1000mbq/ml vial

Pluvicto

lutetium Lu 177 vipivotide tetraxetan
Used for Prostate Cancer
Used for Prostate Cancer

Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radiopharmaceutical that’s used to treat adults with certain castration-resistant prostate cancers that have spread to other parts of the body. It targets cancer cells that have a particular protein on their surface. It’s typically given as an injection through the vein every 6 weeks for up to 6 doses. Talk with your treatment team about keeping yourself and others safe after each treatment because you could expose others to radiation for a few days after each dose. Common side effects include fatigue, nausea, dry mouth, and constipation.

Last reviewed on November 20, 2023
basics-icon

What is Pluvicto (lutetium lu 177 vipivotide tetraxetan)?

What is Pluvicto (lutetium lu 177 vipivotide tetraxetan) used for?

How Pluvicto (lutetium lu 177 vipivotide tetraxetan) works

Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radiopharmaceutical. It attaches a particular protein found on the surface of certain cancer cells called prostate-specific membrane antigen (PSMA). Once attached, the Pluvicto (lutetium lu 177 vipivotide tetraxetan) enters the cell. Then, the radioactive portion of the medication (lutetium-177) causes radiation damage so that the prostate cancer can’t grow or spread as easily.

Are you looking for information on Lutathera (lutetium lu 177 dotatate) instead?

Drug Facts

Common BrandsPluvicto
Drug ClassRadiopharmaceutical
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
basics-icon

What are the side effects of Pluvicto (lutetium lu 177 vipivotide tetraxetan)?

The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.

Common Side Effects

  • Feeling very tired (43%)
  • Dry mouth and throat (39%)
  • Nausea (35%)
  • Anemia (32%)
  • Poor appetite (21%)
  • Constipation (20%)
  • Diarrhea (19%)
  • Vomiting (19%)

Other Side Effects

  • Weight loss
  • Fever
  • Stomach pain
  • Urinary tract infection (UTI)
  • Dizziness
  • Headache
  • Changes in taste

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following.
  • Low blood cell counts: fever, chills, feeling very tired, unusual bleeding or bruising
  • Kidney problems: making little or no urine, dark urine

Source: DailyMed

The following side effects have also been reported

Side effects that you should report to your care team as soon as possible:

  • Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
  • Infection—fever, chills, cough, sore throat, wounds that don't heal, pain or trouble when passing urine, general feeling of discomfort or being unwell
  • Kidney injury—decrease in the amount of urine, swelling of the ankles, hands, or feet
  • Low red blood cell level—unusual weakness or fatigue, dizziness, headache, trouble breathing
  • Unusual bruising or bleeding

Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):

pros-and-cons

Pros and cons of Pluvicto (lutetium lu 177 vipivotide tetraxetan)

thumbs-up

Pros

Recommended treatment for metastatic, castration-resistant prostate cancer after other treatments have stopped working

Treatments are given once every 6 weeks

Targeted therapy, so it works in a more specific way than traditional chemotherapy

thumbs-down

Cons

Often causes fatigue, nausea, and dry mouth

Need to receive the infusion in a specialized clinic by those trained in giving radiopharmaceuticals

Radioactive treatment, so extra safety precautions are needed after treatment

pharmacist-tips

Pharmacist tips for Pluvicto (lutetium lu 177 vipivotide tetraxetan)

pharmacist
  • Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radiation treatment. At the treatment center, you’ll likely be in a separate area to prevent others from radiation exposure. Your treatment team will wear protective equipment and give you instructions on radiation safety after you leave the clinic.

    • For the first few days after each Pluvicto (lutetium lu 177 vipivotide tetraxetan) dose, you’ll still have radiation in your body that could be harmful to others. Try to stay at least 3 ft away from others for the first 2 days after your Pluvicto (lutetium lu 177 vipivotide tetraxetan) dose, and avoid sexual activity with others for 7 days after the dose.

      • Radiation can be especially harmful to children and unborn babies. Limit close contact (closer than 3 feet) with children and pregnant women for 7 days after your Pluvicto (lutetium lu 177 vipivotide tetraxetan) dose. You should also sleep in a separate room from children for 7 days, and from pregnant women for 15 days after each treatment.

        • Drink plenty of water and urinate frequently before and after treatment with Pluvicto (lutetium lu 177 vipivotide tetraxetan). This helps prevent potential kidney damage from the radiation.

          • Pluvicto (lutetium lu 177 vipivotide tetraxetan) can lower blood cell counts, which can raise your risk for infections and bleeding. Let your provider know if you have signs of unusual bleeding or bruising, or signs of an infection, like weakness, trouble breathing, fever, chills, sore throat, or mouth sores.

            • Dry mouth is a common side effect of Pluvicto (lutetium lu 177 vipivotide tetraxetan) . If you’re feeling dryness in your mouth or throat, make sure to stay well-hydrated. You can also try over-the-counter saliva substitutes, sugar-free gum, or lozenges to help relieve your symptoms.

              • Pluvicto (lutetium lu 177 vipivotide tetraxetan) can harm unborn babies and affect fertility. Talk with your provider before starting treatment if you plan on having children. If you have a partner who can become pregnant, continue using effective birth control while on treatment and for 14 weeks after your last dose.

                faqs

                Frequently asked questions about Pluvicto (lutetium lu 177 vipivotide tetraxetan)

                What is the life expectancy with Pluvicto (lutetium lu 177 vipivotide tetraxetan)?
                In a clinical trial, people with prostate cancer who received Pluvicto (lutetium lu 177 vipivotide tetraxetan) were found to live 4 months longer compared to those who received traditional treatment. But this can be different for you since everyone reacts to medications in various ways. Talk to your provider if you have questions about how well this medication might work for you.
                Is Pluvicto (lutetium lu 177 vipivotide tetraxetan) chemotherapy?
                No, Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radiopharmaceutical, not chemotherapy. It targets prostate cancer cells that have a special protein called prostate-specific membrane antigen (PSMA) on their surface, and delivers radiation to those cells. Traditional chemotherapy doesn’t target any specific types of cells, and works against any rapidly growing and dividing cells in the body.
                Who qualifies for Pluvicto (lutetium lu 177 vipivotide tetraxetan)?
                Pluvicto (lutetium lu 177 vipivotide tetraxetan) is approved for metastatic, castration-resistant prostate cancer that has the PSMA protein. And it’s typically given to those who have already received treatment with androgen receptor pathway blockers like abiraterone (Zytiga) or enzalutamide (Xtandi), as well as taxane chemotherapy such as docetaxel (Taxotere). To check if your cancer has PSMA on tumor cells, your provider will have you do a specific PET scan with another medication called Locametz (gallium Ga 68 gozetotide). If your cancer does show high amounts of PSMA, Pluvicto (lutetium lu 177 vipivotide tetraxetan) might be an option for you.
                How many times can you have Pluvicto (lutetium lu 177 vipivotide tetraxetan)?
                Usually, a Pluvicto (lutetium lu 177 vipivotide tetraxetan) treatment course consists of a dose every 6 weeks for up to 6 doses. Your schedule and dose might be different depending on if you have side effects from the medication, like low blood counts or signs of kidney damage. Your provider might also have you stop treatment if they see signs that Pluvicto (lutetium lu 177 vipivotide tetraxetan) isn’t working based on lab tests, scans, or symptoms of your cancer.
                What precautions should be taken after Pluvicto (lutetium lu 177 vipivotide tetraxetan) therapy?
                Following a dose of Pluvicto (lutetium lu 177 vipivotide tetraxetan), radioactivity will remain in your body for several days after the treatment. For the first few days to a week, you’ll need to keep your distance (about 3 feet) away from others, sleep separately, and avoid sexual activity. This is especially important if you’re around someone who’s pregnant. Talk with your provider about any activities you have planned after your Pluvicto (lutetium lu 177 vipivotide tetraxetan) treatments to make sure they’re safe for you and those around you.
                GoodRxEducationalIcon

                How to save using GoodRx

                Compare Prices
                1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
                Select your free coupon
                2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
                Show coupon to your pharmacist
                3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
                Get free couponLearn more
                warings-icon

                What are the risks and warnings for Pluvicto (lutetium lu 177 vipivotide tetraxetan)?

                Pluvicto (lutetium lu 177 vipivotide tetraxetan) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

                risk-warning

                Radiation exposure

                Since Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radiation-based treatment, it can add to your overall radiation exposure over time. And higher total amounts of radiation exposure can raise risk for cancer. Talk with your provider if you’re concerned about radiation exposure, and precautions you can take to protect yourself and others during Pluvicto (lutetium lu 177 vipivotide tetraxetan) treatment.

                risk-warning

                Low blood cell counts (bone marrow suppression)

                Pluvicto (lutetium lu 177 vipivotide tetraxetan) affects your bone marrow and causes your body to make fewer blood cells. Low amounts of blood cells can raise your chance of bleeding and make you more likely to get infections. Your provider will monitor your blood work before each treatment to make sure that your blood cell levels are safe. And if needed, they might make changes to your dosing schedule or dose of Pluvicto (lutetium lu 177 vipivotide tetraxetan). Talk to your healthcare provider right away if you suddenly have unusual bleeding or bruising, muscle weakness, changes in your speech and vision, or develop a fever.

                risk-warning

                Kidney problems

                • Risk factors: History of kidney problems

                  Pluvicto (lutetium lu 177 vipivotide tetraxetan) can harm the kidneys, especially if you’ve had previous kidney problems. Your treatment team will do a blood test to check that your kidneys are healthy before each treatment. It’s a good idea to stay well-hydrated and urinate frequently before and after treatment to keep your kidneys working well. Let your provider know if you have little or no urine. That could be a sign of kidney problems, and you might have to temporarily delay treatment while your kidneys recover.

                  risk-warning

                  Harm to the unborn baby

                  Pluvicto (lutetium lu 177 vipivotide tetraxetan) can harm unborn babies. If you have a partner who’s able to become pregnant, continue using effective birth control while taking Pluvicto (lutetium lu 177 vipivotide tetraxetan) and for at least 14 weeks after the last dose.

                  risk-warning

                  Fertility problems

                  Pluvicto (lutetium lu 177 vipivotide tetraxetan) can lead to infertility. Before starting treatment, talk with your provider if you are planning on having children.

                  dosage

                  Pluvicto (lutetium lu 177 vipivotide tetraxetan) dosage forms

                  Typical dosing for Pluvicto (lutetium lu 177 vipivotide tetraxetan)

                  The typical dose is 7.4 GBq as an injection through the vein about every 6 weeks for up to 6 doses.

                  Your dose might be different if you develop certain side effects to the medication.

                  Note: GBq is a unit of radioactivity. Since this medication works by delivering radiation, the dose is described using units that measure radioactivity.

                  alternatives

                  What are alternatives to Pluvicto (lutetium lu 177 vipivotide tetraxetan)?

                  There are a number of medications that your doctor can prescribe in place of Pluvicto (lutetium lu 177 vipivotide tetraxetan). Compare a few possible alternatives below.
                  Pluvicto (lutetium lu 177 vipivotide tetraxetan)
                  Used for:
                  Used for:
                  • Prostate cancer that has spread to other areas of the body (used in combination with prednisone)

                  images

                  Pluvicto (lutetium lu 177 vipivotide tetraxetan) images

                  yellow - PLUVICTO 1000MBq / mL Solution for Injection
                  This medicine is Yellow Vial.yellow - PLUVICTO 1000MBq / mL Solution for Injection

                  Get savings updates for Pluvicto (lutetium lu 177 vipivotide tetraxetan)

                  Receive price alerts, news, and other messages from GoodRx about Pluvicto (lutetium lu 177 vipivotide tetraxetan) and other healthcare topics and relevant savings offers.

                  By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.

                  References

                  Best studies we found

                  Advanced Accelerator Applications USA, Inc. (2024). Pluvicto- lutetium lu 177 vipivotide textrazetan injection, solution [package insert]. DailyMed.

                  American Cancer Society. (2019). Radiation therapy safety.

                  American Cancer Society. (2023). Radiation therapy for prostate cancer.

                  View All References (8)

                  Chang, S. S. (2004). Overview of prostate-specific membrane antigen. Reviews in Urology.

                  Kratochwil, C., et al. (2023). Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging.

                  Munjal, A., et al. (2023). Radiopharmaceuticals. StatPearls.

                  National Comprehensive Cancer Network. (2023). Advanced-state prostate cancer.

                  Novartis Pharmaceuticals Corporation. (2024). What to expect when taking Pluvicto.

                  Prostate Cancer Foundation. (n.d.). Chemotherapy for prostate cancer.

                  Sartor, O., et al. (2021). Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. The New England Journal of Medicine.

                  United States Nuclear Regulatory Commission. (2021). Becquerel (Bq).

                  GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
                  Was this page helpful?

                  Browse medications

                  View All

                  Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.